Cargando…
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement
BACKGROUND: Basal insulin and premix insulin are commonly prescribed first-line insulin therapies for patients failing to maintain glycaemic control on oral therapy. When control on these insulins starts to drift, premix analogues, such as biphasic insulin aspart 30/70 (BIAsp 30), are a simple and e...
Autores principales: | Unnikrishnan, A G, Tibaldi, J, Hadley-Brown, M, Krentz, A J, Ligthelm, R, Damci, T, Gumprecht, J, Gerő, L, Mu, Y, Raz, I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780562/ https://www.ncbi.nlm.nih.gov/pubmed/19780866 http://dx.doi.org/10.1111/j.1742-1241.2009.02192.x |
Ejemplares similares
-
Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement
por: Brito, Miguel, et al.
Publicado: (2011) -
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009) -
A commentary on the “consensus statement” regarding the use of BIAsp30
por: Kawamori, Ryuzo
Publicado: (2010) -
A healthy bladder: a consensus statement
por: Lukacz, E S, et al.
Publicado: (2011) -
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
por: Zhou, Xiao-Dong, et al.
Publicado: (2023)